Loading…
Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy
Summary Objective While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors. Design Prospective controlled stud...
Saved in:
| Published in: | Clinical endocrinology (Oxford) 2017-03, Vol.86 (3), p.388-394 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3 |
| container_end_page | 394 |
| container_issue | 3 |
| container_start_page | 388 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 86 |
| creator | Cheung, Ada S. Rooy, Casey Hoermann, Rudolf Lim Joon, Daryl Zajac, Jeffrey D. Grossmann, Mathis |
| description | Summary
Objective
While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors.
Design
Prospective controlled study.
Patients
Sixty‐three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age‐ and radiotherapy‐matched prostate cancer controls (n = 29).
Measurements
QoL was measured by Short‐Form 12 version 2 survey (SF‐12) and Aging Males’ Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow‐up.
Results
Compared to controls over 12 months, men receiving ADT had decreased SF‐12 physical component score [MAD −3·61 (−6·94, −0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P |
| doi_str_mv | 10.1111/cen.13249 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1877813525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1877813525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3</originalsourceid><addsrcrecordid>eNqN0ctKJDEUBuAwjGh7WcwLDIHZ6KLspFJJKsuhaS8giqBbi1Ry0kaqUz1JldJvb7TbWQiC2ZwsPn6S8yP0i5JTms_UQDilrKzUDzShTPCiLAX_iSaEEVIQIao9tJ_SEyGE10Tuor1SCiUqxSfo4XbUnR_WuHe48w6wBRNhCWFI2AecL_jFD494Ffs06AGw0cFAxGOwEBe9Dwusg439IkMLq-if9eD7gIdHiHq1PkQ7TncJjrbzAN2fze9mF8XVzfnl7O9VYaqSqoJWtSREA60tZcCBtaqlDqTUruaSUktt64yULa215aSsTK2YtgRU62zVOnaAjje5-Z3_RkhDs_TJQNfpAP2YGlpLWVPGS_4NyjiTQrIy0z-f6FM_xpA_kpVQinAp3gJPNsrkHaUIrslrWOq4bihp3vppcj_Nez_Z_t4mju0S7H_5UUgG0w148R2sv05qZvPrTeQrCheZ9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869905765</pqid></control><display><type>article</type><title>Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy</title><source>Wiley</source><creator>Cheung, Ada S. ; Rooy, Casey ; Hoermann, Rudolf ; Lim Joon, Daryl ; Zajac, Jeffrey D. ; Grossmann, Mathis</creator><creatorcontrib>Cheung, Ada S. ; Rooy, Casey ; Hoermann, Rudolf ; Lim Joon, Daryl ; Zajac, Jeffrey D. ; Grossmann, Mathis</creatorcontrib><description>Summary
Objective
While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors.
Design
Prospective controlled study.
Patients
Sixty‐three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age‐ and radiotherapy‐matched prostate cancer controls (n = 29).
Measurements
QoL was measured by Short‐Form 12 version 2 survey (SF‐12) and Aging Males’ Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow‐up.
Results
Compared to controls over 12 months, men receiving ADT had decreased SF‐12 physical component score [MAD −3·61 (−6·94, −0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P < 0·001], reflecting worse QoL. Both SF‐12 and AMS changes were greater than reported minimum clinically important differences. AMS sub‐domains showed increased somatic [MAD 3·96 (1·94, 5·99), P < 0·001] and sexual [MAD 3·80 (2·16, 5·44), P < 0·001] components but not psychological (P = 0·19). Decrements were related to an increase in hot flushes (P = 0·016) but not haemoglobin decrease (P = 0·46).
Conclusions
Within 12 months, ADT is associated with clinically significant decreased QoL, particularly physical and sexual aspects, independent of the confounding effects of a cancer diagnosis or radiotherapy. As QoL is a crucial aspect of prostate cancer treatment, addressing hot flushes, sexual dysfunction and exercise may potentially improve outcomes for men undergoing ADT.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/cen.13249</identifier><identifier>PMID: 27696495</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Androgen Antagonists - therapeutic use ; Case-Control Studies ; Exercise ; Humans ; Male ; Middle Aged ; Prospective Studies ; Prostatic Neoplasms - psychology ; Quality of Life ; Sexual Dysfunction, Physiological ; Surveys and Questionnaires</subject><ispartof>Clinical endocrinology (Oxford), 2017-03, Vol.86 (3), p.388-394</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3</citedby><cites>FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3</cites><orcidid>0000-0001-5257-5525</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27696495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung, Ada S.</creatorcontrib><creatorcontrib>Rooy, Casey</creatorcontrib><creatorcontrib>Hoermann, Rudolf</creatorcontrib><creatorcontrib>Lim Joon, Daryl</creatorcontrib><creatorcontrib>Zajac, Jeffrey D.</creatorcontrib><creatorcontrib>Grossmann, Mathis</creatorcontrib><title>Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
Objective
While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors.
Design
Prospective controlled study.
Patients
Sixty‐three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age‐ and radiotherapy‐matched prostate cancer controls (n = 29).
Measurements
QoL was measured by Short‐Form 12 version 2 survey (SF‐12) and Aging Males’ Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow‐up.
Results
Compared to controls over 12 months, men receiving ADT had decreased SF‐12 physical component score [MAD −3·61 (−6·94, −0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P < 0·001], reflecting worse QoL. Both SF‐12 and AMS changes were greater than reported minimum clinically important differences. AMS sub‐domains showed increased somatic [MAD 3·96 (1·94, 5·99), P < 0·001] and sexual [MAD 3·80 (2·16, 5·44), P < 0·001] components but not psychological (P = 0·19). Decrements were related to an increase in hot flushes (P = 0·016) but not haemoglobin decrease (P = 0·46).
Conclusions
Within 12 months, ADT is associated with clinically significant decreased QoL, particularly physical and sexual aspects, independent of the confounding effects of a cancer diagnosis or radiotherapy. As QoL is a crucial aspect of prostate cancer treatment, addressing hot flushes, sexual dysfunction and exercise may potentially improve outcomes for men undergoing ADT.</description><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Exercise</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Prostatic Neoplasms - psychology</subject><subject>Quality of Life</subject><subject>Sexual Dysfunction, Physiological</subject><subject>Surveys and Questionnaires</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqN0ctKJDEUBuAwjGh7WcwLDIHZ6KLspFJJKsuhaS8giqBbi1Ry0kaqUz1JldJvb7TbWQiC2ZwsPn6S8yP0i5JTms_UQDilrKzUDzShTPCiLAX_iSaEEVIQIao9tJ_SEyGE10Tuor1SCiUqxSfo4XbUnR_WuHe48w6wBRNhCWFI2AecL_jFD494Ffs06AGw0cFAxGOwEBe9Dwusg439IkMLq-if9eD7gIdHiHq1PkQ7TncJjrbzAN2fze9mF8XVzfnl7O9VYaqSqoJWtSREA60tZcCBtaqlDqTUruaSUktt64yULa215aSsTK2YtgRU62zVOnaAjje5-Z3_RkhDs_TJQNfpAP2YGlpLWVPGS_4NyjiTQrIy0z-f6FM_xpA_kpVQinAp3gJPNsrkHaUIrslrWOq4bihp3vppcj_Nez_Z_t4mju0S7H_5UUgG0w148R2sv05qZvPrTeQrCheZ9g</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Cheung, Ada S.</creator><creator>Rooy, Casey</creator><creator>Hoermann, Rudolf</creator><creator>Lim Joon, Daryl</creator><creator>Zajac, Jeffrey D.</creator><creator>Grossmann, Mathis</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5257-5525</orcidid></search><sort><creationdate>201703</creationdate><title>Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy</title><author>Cheung, Ada S. ; Rooy, Casey ; Hoermann, Rudolf ; Lim Joon, Daryl ; Zajac, Jeffrey D. ; Grossmann, Mathis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Exercise</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Prostatic Neoplasms - psychology</topic><topic>Quality of Life</topic><topic>Sexual Dysfunction, Physiological</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung, Ada S.</creatorcontrib><creatorcontrib>Rooy, Casey</creatorcontrib><creatorcontrib>Hoermann, Rudolf</creatorcontrib><creatorcontrib>Lim Joon, Daryl</creatorcontrib><creatorcontrib>Zajac, Jeffrey D.</creatorcontrib><creatorcontrib>Grossmann, Mathis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung, Ada S.</au><au>Rooy, Casey</au><au>Hoermann, Rudolf</au><au>Lim Joon, Daryl</au><au>Zajac, Jeffrey D.</au><au>Grossmann, Mathis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2017-03</date><risdate>2017</risdate><volume>86</volume><issue>3</issue><spage>388</spage><epage>394</epage><pages>388-394</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><abstract>Summary
Objective
While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors.
Design
Prospective controlled study.
Patients
Sixty‐three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age‐ and radiotherapy‐matched prostate cancer controls (n = 29).
Measurements
QoL was measured by Short‐Form 12 version 2 survey (SF‐12) and Aging Males’ Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow‐up.
Results
Compared to controls over 12 months, men receiving ADT had decreased SF‐12 physical component score [MAD −3·61 (−6·94, −0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P < 0·001], reflecting worse QoL. Both SF‐12 and AMS changes were greater than reported minimum clinically important differences. AMS sub‐domains showed increased somatic [MAD 3·96 (1·94, 5·99), P < 0·001] and sexual [MAD 3·80 (2·16, 5·44), P < 0·001] components but not psychological (P = 0·19). Decrements were related to an increase in hot flushes (P = 0·016) but not haemoglobin decrease (P = 0·46).
Conclusions
Within 12 months, ADT is associated with clinically significant decreased QoL, particularly physical and sexual aspects, independent of the confounding effects of a cancer diagnosis or radiotherapy. As QoL is a crucial aspect of prostate cancer treatment, addressing hot flushes, sexual dysfunction and exercise may potentially improve outcomes for men undergoing ADT.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27696495</pmid><doi>10.1111/cen.13249</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-5257-5525</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2017-03, Vol.86 (3), p.388-394 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1877813525 |
| source | Wiley |
| subjects | Aged Androgen Antagonists - therapeutic use Case-Control Studies Exercise Humans Male Middle Aged Prospective Studies Prostatic Neoplasms - psychology Quality of Life Sexual Dysfunction, Physiological Surveys and Questionnaires |
| title | Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T10%3A54%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20decrements%20in%20men%20with%20prostate%20cancer%20undergoing%20androgen%20deprivation%20therapy&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Cheung,%20Ada%20S.&rft.date=2017-03&rft.volume=86&rft.issue=3&rft.spage=388&rft.epage=394&rft.pages=388-394&rft.issn=0300-0664&rft.eissn=1365-2265&rft_id=info:doi/10.1111/cen.13249&rft_dat=%3Cproquest_cross%3E1877813525%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4219-148700ae18d13e5e3b9b1fe77af85711d1dbfc77b18ad5024c893ad0e9bfd4bf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1869905765&rft_id=info:pmid/27696495&rfr_iscdi=true |